The chemotherapy-free regimen achieved higher remission, better survival, and stronger molecular responses than the ...

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of ...

Objectives Delays in cancer diagnosis for patients with non-specific symptoms (NSSs) lead to poorer outcomes. Rapid ...

At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.

Acute myeloid leukemia (AML) is a malignancy characterized by the clonal proliferation of myeloid hematopoietic progenitor or stem cells, primarily ...

Novartis Canada is pleased to announce that Scemblix® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario’s new ...

A pioneering genetic treatment is saving lives where chemotherapy failed, offering new hope for children and adults with ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...

At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining ...